Tracking when private companies are nearing a sale, recap, or financing event has always been a guessing game. With thousands of sponsor-backed firms spread across sectors and geographies, most deal teams are forced to react after the market moves.
Investors, bankers, and service providers struggle to know which private companies are gearing up for a transaction or capital raise. Signals are scattered, opaque, and nearly impossible to track across thousands of PE- and VC-backed businesses.
Dakota centralizes those signals (holding periods, funding rounds, platform acquisition dates, ownership changes, and exit timing patterns) into one predictive transaction-readiness tool. Instead of waiting for headlines, users can see which companies are showing the strongest likelihood of pursuing a sale, recapitalization, or new financing before the market knows.
Below is today’s list of five PE- or VC-backed companies that, based on their hold period, financing stage, and last transaction date, appear to be credible candidates for a sale or next-round raise.
Nothing is guaranteed, but these companies fall squarely within the timing windows where sponsors typically look to generate liquidity or secure additional capital.
Sourced from Dakota Sponsor Backed Companies.
1. Inductive Bio
Inductive Bio is a biotechnology company specializing in accelerating small molecule drug discovery by addressing ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) challenges. Their platform integrates machine learning models, a comprehensive data consortium, and generative chemistry to optimize compound development, enabling faster and more efficient therapeutic advancements.
- Sector: Health Care
- Last known transaction date: Series A Venture, $25M, May 2025
- Why timing suggests a near-term transaction: A $25M Series A in May 2025 typically provides 18–24 months of runway for a healthcare company, placing Inductive Bio squarely in the window for a Series B raise by late 2026 to early 2027 — especially as clinical or product milestones from Series A deployment approach proof-of-concept stage and investor appetite for healthcare AI and biotech remains strong.
View all private company data in Dakota Marketplace.
2. Eyeo
Eyeo Imaging is a Netherlands-based company specializing in advanced image sensor technology. Founded in November 2024, the company is headquartered in Eindhoven, with a research and development office in Leuven, Belgium. Eyeo Imaging's mission is to revolutionize image sensing by developing sensors that capture all incoming light, overcoming the limitations of traditional color filter technology. Their proprietary color-splitting technology utilizes nanophotonic structures to guide photons directly to individual pixels, enhancing light sensitivity, color accuracy, and resolution. This innovation has applications across various sectors, including consumer electronics, automotive, medical imaging, and security.
- Sector: Information Technology
- Last known transaction date: Seed Venture, $17M, May 2025
- Why timing suggests a near-term transaction: A $17M seed round in May 2025 typically provides 18–24 months of runway for an IT company, positioning Eyeo for a Series A raise by late 2026 to early 2027 as the capital is deployed toward product-market fit milestones and early revenue traction that institutional Series A investors expect to see.
View all private company data in Dakota Marketplace.
3. Uviquity
Uviquity is a technology company specializing in human-safe, pathogen-eliminating far-UVC light solutions. Their proprietary semiconductor chips generate far-UVC light, effectively inactivating viruses, bacteria, fungi, and mold spores in occupied spaces. This technology is designed to provide continuous disinfection for air, water, and food without the use of chemicals or waste.
- Sector: Information Technology
- Last known funding round: Seed Venture, $6.6M, May 2025
- Why timing suggests a near-term transaction: A $6.6M seed round in May 2025 carries a tighter runway of 12–18 months for an IT company given the smaller raise size, suggesting Uviquity is likely already in active fundraising mode for a Series A and could close a round as early as mid-to-late 2026 as it looks to accelerate growth ahead of capital depletion.
View all private company data in Dakota Marketplace.
4. Avammune Therapeutics
Avammune Therapeutics is a biotechnology company specializing in the discovery and development of small-molecule drugs that modulate the innate immune system to treat cancer. Founded in 2017 by Arun B. Papaiah, Dr. Aditya Kulkarni, and Srinivasan Namala, the company is headquartered in Philadelphia, Pennsylvania. Avammune's approach integrates novel target biology, immunology, computational chemistry, and advances in parallel/high-throughput chemistry to identify novel targets and develop a proprietary pipeline of best-in-class and first-in-class small-molecule drug candidates for potential use in oncology. The company's lead drug candidate, AVA-NP-695, is an ENPP1 inhibitor that has shown promising preclinical anti-tumor activity.
- Sector: Health Care
- Last known funding round: Series A Venture, $12M, May 2025
- Why timing suggests a near-term transaction: A $12M Series A in May 2025 is on the smaller end for a therapeutics company, where R&D and clinical burn rates are high, suggesting a runway of roughly 12–18 months and placing Avammune in the fundraising window for a Series B by late 2026 — particularly if early preclinical or IND-enabling data from the Series A period are ready to support the next raise.
View all private company data in Dakota Marketplace.
5. Wonderskin
Wonderskin is a beauty brand specializing in makeup and skincare products, including lip stains, eyeliners, and skincare solutions. Founded in 2020 and headquartered in Fair Lawn, New Jersey, the company is known for its Wonder Blading technology, which offers transfer-proof and waterproof lip color. Wonderskin focuses on creating products that meet the needs of beauty consumers while ensuring skin-friendly formulas. The leadership team includes CEO Michael Malinsky, who previously served as CEO and Co-Founder of Wunder2. The company's mission is to innovate and disrupt the beauty industry by developing clean, high-tech products that deliver amazing results. Recent developments include the launch of their first foundation in 20 shades and the debut of their Wonder Blading Lip Stains at Sephora.
- Sector: Consumer Discretionary
- Last known funding round: Series A Venture, $50M, May 2025
- Why timing suggests a near-term transaction: A $50M Series A in May 2025 provides a consumer brand with a relatively extended runway of 24–36 months, but the scale of the raise also signals investor conviction and growth ambitions that typically drive a return to market sooner — positioning Wonderskin for a Series B raise by mid-to-late 2027 as it deploys capital toward retail expansion, marketing, and revenue scale milestones that growth-stage investors expect.
View all private company data in Dakota Marketplace.
Use Dakota’s Sponsor Backed Company Intelligence to Spot Likely Exits Before the Market Does
Dakota’s private company data gives you a real-time view into thousands of sponsor-backed companies, including platform acquisition dates, funding rounds, parent sponsors, add-on activity, and sector categorization.
Instead of guessing where companies are in their lifecycle, you can instantly identify which ones are approaching the typical timing windows for a sale or recap.
Fully integrated into Dakota Marketplace, this dataset enables deal sourcers, investor relations teams, and allocators to anticipate transactions, build targeted outreach lists, and stay ahead of market announcements, every single day.
To explore more companies likely to transact, book a demo of Dakota Marketplace!
